University Institute of Cardiology and Pneumology of Quebec
Welcome,         Profile    Billing    Logout  
 7 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Healey, Jeff
ARTESiA, NCT01938248 / 2014-001397-33: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Completed
4
4012
Europe, Canada, US, RoW
Apixaban, Eliquis, aspirin, ASA, acetylsalicylic acid
Population Health Research Institute, Bristol-Myers Squibb, Pfizer, Medtronic, Canadian Institutes of Health Research (CIHR)
Atrial Fibrillation, Stroke
10/23
11/23
VANISH2, NCT02830360: Antiarrhythmics or Ablation for Ventricular Tachycardia 2

Completed
4
416
Europe, Canada, US
Antiarrythmic Drug Therapy, Amiodarone (Cordarone) or Sotalol (Sotacor), Catheter ablation, VT ablation
John Sapp, Heart and Stroke Foundation of Canada, Abbott Medical Devices, Biosense Webster, Inc., Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Cardiac Arrhythmia Network of Canada, Abbott, Nova Scotia Health Authority
Ventricular Tachycardia (VT)
06/24
06/24
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
TaRGET, NCT06174220: Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Not yet recruiting
2
120
Canada
Tideglusib, Placebo
Hamilton Health Sciences Corporation, Population Health Research Institute, Canadian Institutes of Health Research (CIHR), AMO Pharma, Hearts in Rhythm Organization (HiRO), Canadian SADS
Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
02/26
07/26
EPS ARREST, NCT03079414: The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

Recruiting
N/A
100
Canada, US, RoW
Invasive Electrophysiology Study
Western University, Canada, Canadian Institutes of Health Research (CIHR)
Sudden Cardiac Death
01/25
01/25
RAFT-AF Extend, NCT05118893: Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

Recruiting
N/A
311
Canada
Anthony Tang
Atrial Fibrillation, Heart Failure
09/24
09/24
RAFT-PermAF, NCT01994252: Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

Active, not recruiting
N/A
200
Canada
Optimal Medical therapy plus ICD, Optimal Medical therapy plus CRT/ICD
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR)
Heart Disease, Congestive Heart Failure, Atrial Fibrillation
09/24
09/24
RASTA AF, NCT03682991: Reversal of Atrial Substrate to Prevent Atrial

Recruiting
N/A
670
Canada
Aggressive Risk Factor Control, Standard of Care
Nova Scotia Health Authority, Canadian Institutes of Health Research (CIHR), Abbott, Phillips, Cardiac Arrhythmia Network of Canada
Atrial Fibrillation
06/25
06/27
CHASM-CS, NCT01477359: Cardiac Sarcoidosis Multi-Center Prospective Cohort

Recruiting
N/A
1500
Canada, Japan
Ottawa Heart Institute Research Corporation, Ontario Ministry of Health and Long Term Care, Canadian Institutes of Health Research (CIHR)
Cardiac Sarcoidosis
12/25
12/25
LAAOS-4, NCT05963698: The Fourth Left Atrial Appendage Occlusion Study

Recruiting
N/A
4000
Europe, Canada, US
WATCHMAN device
Hamilton Health Sciences Corporation, McMaster University, Population Health Research Institute, Boston Scientific Corporation
Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
09/29
12/29
Belliveau, Daniel
TaRGET, NCT06174220: Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Not yet recruiting
2
120
Canada
Tideglusib, Placebo
Hamilton Health Sciences Corporation, Population Health Research Institute, Canadian Institutes of Health Research (CIHR), AMO Pharma, Hearts in Rhythm Organization (HiRO), Canadian SADS
Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
02/26
07/26
NCT05149755: Evolut™ EXPAND TAVR II Pivotal Trial

Recruiting
N/A
650
Europe, Canada, Japan, US, RoW
Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
Medtronic Cardiovascular
Moderate Aortic Valve Stenosis
02/26
12/34

Download Options